2012 European guideline on the diagnosis and treatment of gonorrhoea in adults

International Journal of STD and AIDS

Volumn 24, Issue 2, 2013, Pages 85-92

  Bignell, C ^a   Unemo, M ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotic; Antimicrobial resistance; Antimicrobial treatment; Diagnosis; European clinical guideline; Gonorrhoea; Management; Neisseria gonorrhoeae

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DOXYCYCLINE; GENTAMICIN; MACROLIDE; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE DERIVATIVE;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTHRALGIA; ARTICLE; ASYMPTOMATIC INFECTION; BREAST FEEDING; CHLAMYDIASIS; CLINICAL FEATURE; CONTACT EXAMINATION; CROSS ALLERGY; CULTURE MEDIUM; DRUG EFFICACY; DRUG SAFETY; DYSURIA; EUROPE; FEVER; FOLLOW UP; GENITAL TRACT INFECTION; GONORRHEA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOWER ABDOMINAL PAIN; METRORRHAGIA; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NEWBORN OPHTHALMIA; NUCLEIC ACID AMPLIFICATION; PATIENT INFORMATION; PENICILLIN ALLERGY; PREDICTIVE VALUE; PREGNANCY; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SKIN DEFECT; TENOSYNOVITIS; TREATMENT FAILURE; URETHRITIS; URINALYSIS; UTERINE CERVICITIS; UTERINE ENDOCERVIX; VAGINA DISCHARGE; WORLD HEALTH ORGANIZATION;

EID: 84879495636     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1177/0956462412472837     Document Type: Article

References (84)

1. World Health Organization. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections-2008. http://www.who.int/ reproductivehealth/publications/rtis/2008_STI_estimates.pdf (last checked 10 November 2012)
2. European Centre for Disease Prevention and Control (ECDC). Sexually Transmitted Infections in Europe, 1990-2010. See http://www.ecdc.europa.eu/ en/publications/Publications/ 201206-Sexually-Transmitted-Infections-Europe-2010.pdf (last checked 10 November 2012)
3. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) Year 2010 Report. http://www.hpa.org.uk/webc/ HPAwebFile/HPAweb_C/1316016752917 (last checked 10 November 2012)
4. Risley CL, Ward H, Choudhury B, et al. Geographical and demographic clustering of gonorrhoea in London. Sex Transm Infect 2007;83:481-7
5. Hook EW III, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, et al., eds. Sexually Transmitted Diseases. 4th edn. New York, NY: McGraw Hill, 2008:627-45
6. Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med 1996;72:422-6
7. Lewis DA, Bond M, Butt KD, Smith CP, Shafi MS, Murphy SM. A one-year survey of gonococcal infection seen in the genitourinary medicine department of a London district general hospital. Int J STD AIDS 1999;10:588-94
8. Barlow D, Phillips I. Gonorrhoea in women: diagnostic, clinical and laboratory aspects. Lancet 1978;1:761-4
9. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California 2003. Clin Infect Dis 2005;41:67-74
10. Peters RPH, Nijsten N, Mutsaers J, Jansen CL, Morre SA, van Leeuwen AP. Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex Transm Dis 2011;38:783-7
11. Bleich AT, Sheffield JS, Wendel GD Jr, Sigman A, Cunningham FG. Disseminated gonococcal infection in women. Obstet Gynecol 2012;119:597-602
12. O'Brien JP, Goldenberg DL, Rice PA. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine 1983;62:395-406
13. Taylor SN, DiCarlo RP, Martin DH. Comparison of methylene blue/gentian violet stain to Gram's stain for the rapid diagnosis of gonococcal urethritis in men. Sex Transm Dis 2011;38:995-6
14. Jephcott AE. Microbiological diagnosis of gonorrhoea. Genitourin Med 1997;73:245-52
15. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011;16:p11-19792
16. Whiley DM, Goire N, Lahra MM, et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012;67:2059-61
17. Cook RL, Hutchison SL, Østergaard L, Braithwaite RS, Ness RB. Systematic review: non-invasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005;142:914-25
18. Whiley DM, Garland SM, Harnett G, et al. Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae. Sex Health 2008;5:17-23
19. Harryman L, Scofield S, Macleod J, et al. Comparative performance of culture using swabs transported in Amies medium and the Aptima Combo 2 nucleic acid amplification test in detection of Neisseria gonorrhoeae from genital and extra-genital sites: a retrospective study. Sex Transm Infect 2012;88:127-31
20. Van Dyck E, Ieven M, Pattyn S, Van Damme L, Laga M. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture and three nucleic acid amplification tests. J Clin Microbiol 2001;39:1751-6
21. Van der Pol B, Ferrero DV, Buck-Barrington L, et al. Multicenter evaluation of the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical and male urethral swabs. J Clin Microbiol 2001;39:1008-16
22. Moncada J, Schachter J, Hook EW III, et al. The effect of urine testing in evaluations of the sensitivity of the Gen-Probe APTIMA Combo 2 Assay on endocervical swabs for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis 2004;31:273-7
23. Chernesky MA, Martin DH, Hook EW, et al. Ability of new APTIMA CT and APTIMA GC Assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol 2005;43:127-31
24. Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005;32:725-8
25. Ison C. GC NAATs: is the time right? Sex Transm Infect 2006;82:515
26. Association of Public Health Laboratories. Laboratory Diagnostic Testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Expert consultation meeting summary report, 13-15 January 2009, Atlanta, GA. See http://www.aphl.org/ aphlprograms/infectious/std/documents/ctgclabguidelinesmeetingreport. pdf (last checked 10 November 2012)
27. Smith DW, Tapsall JW, Lum G. Guidelines for the use and interpretation of nucleic acid detection tests for Neisseria gonorrhoeae in Australia: a position paper on behalf of the Public Health Laboratory Network. Commun Dis Intell 2005;29:358-65
28. Department of Health, Health Protection Agency and BASHH Feb 2010. Guidance for Gonorrhoea Testing in England and Wales. See http://www.bashh. org/guidelines (2010 HPA guidance on Gonorrhoea testing in England & Wales) (last checked 10 November 2012)
29. Page-Shafer K, Graves A, Kent C, Bals JE, Zapitz VM, Klausner JD. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhoea in men who have sex with men. Clin Infect Dis 2002;34:173-6
30. McNally LP, Templeton DJ, Jin F, et al. Low positive predictive value of a nucleic acid amplification test for nongenital Neisseria gonorrhoeae infection in homosexual men. Clin Infect Dis 2008;47:e25-7
31. Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections in the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008;35:637-42
32. Ota KV, Tamari IE, Smieja M, et al. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. Sex Transm Infect 2009;85:182-6
33. Alexander S. The challenges of detecting gonorrhoea and chlamydia in rectal and pharyngeal sites: could we, should we, be doing more? Sex Transm Infect 2009;85:159-60
34. Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010;48:1827-32
35. Mimiaga MJ, Helms DJ, Reisner SL, et al. Gonococcal, chlamydia, and syphilis infection positivity among MSM attending a large primary care clinic, Boston, 2003 to 2004. Sex Transm Dis 2009;36:507-11
36. Palmer H, Mallinson H, Wood RL, Herring AJ. Evaluation of the specificities of five DNA amplification methods for the detection of Neisseria gonorrhoeae. J Clin Microbiol 2003;41:835-7
37. Tabrizi SN, Unemo M, Limnios AE, et al. Evaluation of six commercial nucleic acid amplification tests for the detection of Neisseria gonorrhoeae and other Neisseria species. J Clin Microbiol 2011;49:3610-5
38. Lavelle SJ, Jones KE, Mallinson H, Webb AMC. Finding, confirming, and managing gonorrhea in a population screened for chlamydia using the Gen-Probe Aptima Combo2 assay. Sex Transm Infect 2006;82:221-4
39. Jin F, Prestage GP, Mao L, et al. Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men study. Sex Transm Infect 2007;83:113-9
40. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34
41. European Centre for Disease Prevention and Control (ECDC). Gonococcal Antimicrobial Susceptibility Surveillance in Europe 2010. See http://ecdc.europa. eu/en/publications/Publications/1206-Gonococcal-AMR.pdf (last checked 10 November 2012)
42. Chisholm S, Mouton J, Lewis D, Nichols T, Ison C, Livermore D. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010;65:2141-8
43. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011;55:3538-45
44. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime-and ceftriaxone-resistant N. gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56:1273-80
45. Unemo M, Golparian D, Syversen G, Vestrheim DF, Mol H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15:pii-19721
46. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16:p11-19833
47. Unemo M, Golparian D, Stary A, Eigentler A. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria. Euro Surveill 2011;16:pii-19998
48. Unemo M, Golparian D, Potočnik M, Jeverica S. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 2012;17:pii-20200
49. Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS 2011;22:296-7
50. World Health Organization (WHO), Department of Reproductive Health and Research. Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae. See http://whqlibdoc.who.int/publications/ 2012/9789241503501_eng.pdf (last checked 10 November 2012)
51. European Centre for Disease Prevention and Control (ECDC). Response Plan to Control and Manage the Threat of Multidrug-resistant Gonorrhoea in Europe. See http://www.ecdc.europa.eu/en/publications/Publications/ 1206-ECDC-MDR-gonorrhoea-response-plan.pdf (last checked 10 November 2012)
52. Centers for Disease Control and Prevention (CDC). Cephalosporin-resistant Neisseria gonorrhoeae Public Health Response Plan. See http://www.cdc.gov/std/ gonorrhea/default.htm (last checked 10 November 2012)
53. Furuya R, Nakayama H, Kanayama A, et al. In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006;12:172-6
54. Sathia L, Ellis B, Phillip S, Winston A, Smith A. Pharyngeal gonorrhoea-is dual therapy the way forward? Int J STD AIDS 2007;18:647-8
55. Golden M, Kerani R, Shafii T, Whittington W, Holmes K. Does Azithromycin Co-treatment Enhance the Efficacy of Oral Cephalosporins for Pharyngeal Gonorrhea? Presented at: 18th International Society for STD Research (ISSTDR) Conference, London, UK, June 2009
56. Moran JS, Levine WC. Drugs of choice in the treatment of uncomplicated gonococcal infection. Clin Infect Dis 1995;20(Suppl. 1):S47-65
57. Bignell C, Fitzgerald M, BASHH Guideline Development Group. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011;22:541-7
58. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(No. RR-12):49-55
59. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012;61:590-4
60. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhoea in adults in the United States. Clin Infect Dis 2007;44:S84-101
61. Ison CA, Mouton JW, Jones K, Fenton KA, Livermore DA. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004;80:386-8
62. Moran JS. Ciprofloxacin for gonorrhea-250 mg or 500 mg? Sex Transm Dis 1996;23:165-7
63. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs ceftriaxone in the treatment of uncomplicated gonorrhoea. Sex Transm Dis 1994;21:107-11
64. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010;86:422-6
65. Palmer HM, Young H, Winter A, Dave J. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Antimicrob Chemother 2008;62:490-4
66. Chisholm SA, Neal TJ, Alawattegama AB, Birley HDL, Howe RA, Ison CA. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009;64:353-8
67. Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 2010;54:3812-6
68. Starnino S, Stefanelli P; Neisseria gonorrhoeae Italian Study Group. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J Antimicrob Chemother 2009;63:1200-4
69. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997;8:299-302
70. Tapsall JW, Schultz TR, Limnios EA, Donovan B, Lum G, Mulhall BP. Failure of azithromycin therapy in gonorrhoea and discorrelation with laboratory parameters. Sex Transm Dis 1998;25:505-8
71. Ota KV, Fisman DN, Tamari IE, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis 2009;48:1237-43
72. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995;22:39-47
73. Ross JDC, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012;88:6-8
74. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect 2012;88:589-94
75. Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010;37:169-72
76. Chisholm SA, Quaye N, Cole MJ, et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother 2011;66:592-5
77. Ramus RM, Sheffield JS, Mayfield JA, Wendel GD. A randomised trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhoea in pregnancy. Am J Obstet Gynecol 2001;185:629-32
78. Sandoz Limited. SPC on Azithromycin 28/09/2010. See http://www.medicines. org.uk/EMC/medicine/21720/SPC/Azithromycin+500mg+Tablets/ #PREGNANCY (last checked 10 November 2012)
79. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg 2007;136:340-7
80. Yates AB. Management of patients with a history of allergy to beta-lactam antibiotics. Am J Med 2008;121:572-6
81. Wise CM, Morris CR, Wasilauskas BL, Salzer WL. Gonococcal arthritis in an era of increasing penicillin resistance. Presentations and outcomes in 41 recent cases (1985-1991). Arch Intern Med 1994;154:2690-5
82. Thompson SE. Treatment of disseminated gonococcal infections. Sex Transm Dis 1979;6(Suppl. 1):181-4
83. Hjelmevoll SO, Olsen ME, Sollid JU, et al. Appropriate time for test-of-cure when diagnosing gonorrhoea with a nucleic acid amplification test. Acta Dermatol Venereol 2012;92:316-9
84. Bachmann LH, Desmond RA, Stephens J, Hughes A, Hook EW III. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol 2002;40:3596-601